Becton Dickinson/$BDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Becton Dickinson
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
Ticker
$BDX
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
74,000
ISIN
US0758871091
Website
Becton Dickinson Metrics
BasicAdvanced
$48B
32.65
$5.16
0.38
$3.98
2.47%
Price and volume
Market cap
$48B
Beta
0.38
52-week high
$251.99
52-week low
$163.33
Average daily volume
2.9M
Dividend rate
$3.98
Financial strength
Current ratio
1.127
Quick ratio
0.483
Long term debt to equity
69.989
Total debt to equity
76.344
Dividend payout ratio (TTM)
76.77%
Interest coverage (TTM)
5.33%
Profitability
EBITDA (TTM)
5,558
Gross margin (TTM)
46.32%
Net profit margin (TTM)
7.18%
Operating margin (TTM)
15.35%
Effective tax rate (TTM)
10.99%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
3.67%
Return on equity (TTM)
5.89%
Valuation
Price to earnings (TTM)
32.655
Price to revenue (TTM)
2.335
Price to book
1.91
Price to tangible book (TTM)
-4.26
Price to free cash flow (TTM)
18.804
Free cash flow yield (TTM)
5.32%
Free cash flow per share (TTM)
896.55%
Dividend yield (TTM)
2.36%
Forward dividend yield
2.47%
Growth
Revenue change (TTM)
5.84%
Earnings per share change (TTM)
14.07%
3-year revenue growth (CAGR)
3.31%
10-year revenue growth (CAGR)
9.46%
3-year earnings per share growth (CAGR)
-6.58%
10-year earnings per share growth (CAGR)
-0.54%
3-year dividend per share growth (CAGR)
5.39%
10-year dividend per share growth (CAGR)
5.68%
What the Analysts think about Becton Dickinson
Analyst ratings (Buy, Hold, Sell) for Becton Dickinson stock.
Bulls say / Bears say
BD's planned $2.5 billion investment in U.S. manufacturing over the next five years aims to strengthen its position as the largest U.S. medical device manufacturer, potentially enhancing domestic production capabilities and reducing reliance on foreign manufacturing. (Benzinga)
The FDA's 510(k) clearance of the BD Alaris Infusion System allows BD to resume full commercial operations of this comprehensive infusion system in the U.S., potentially boosting sales and market share. (Benzinga)
BD's acquisition of Edwards Lifesciences' Critical Care product group is expected to significantly enhance its Advanced Patient Monitoring segment, contributing to projected revenue growth of 8.8%-9.3% in FY25. (Seeking Alpha)
BD lowered its fiscal year 2025 earnings guidance to $14.06–$14.34 per share, down from the previous $14.30–$14.60, due to an anticipated $0.25 per share impact from tariffs, indicating potential profitability challenges. (Benzinga)
The company reported first-quarter 2025 sales of $5.27 billion, missing analyst expectations of $5.35 billion, which may raise concerns about its ability to meet revenue targets. (Benzinga)
BD settled charges with the SEC for misleading investors about risks associated with its Alaris infusion pump, resulting in a $175 million penalty, which could impact investor confidence and financial stability. (Sirius Investors)
Data summarised monthly by Lightyear AI. Last updated on 29 May 2025.
Becton Dickinson Financial Performance
Revenues and expenses
Becton Dickinson Earnings Performance
Company profitability
Becton Dickinson News
AllArticlesVideos
UNH, TGT, BDX: 3 Ridiculously Undervalued Stocks Set to Surge in May 2025
24/7 Wall Street·1 month ago
Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years
Benzinga·2 months ago
Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales
Market Watch·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jun30
Becton Dickinson
Dividend·Payment
$1.04Per share
FAQs
What’s the current market cap for Becton Dickinson stock?
Becton Dickinson (BDX) has a market cap of $48B as of June 20, 2025.
What is the P/E ratio for Becton Dickinson stock?
The price to earnings (P/E) ratio for Becton Dickinson (BDX) stock is 32.65 as of June 20, 2025.
Does Becton Dickinson stock pay dividends?
Yes, the Becton Dickinson (BDX) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $3.98 and the yield is 2.47%. Becton Dickinson has a payout ratio of 76.77% on a trailing twelve-month basis.
When is the next Becton Dickinson dividend payment date?
The next Becton Dickinson (BDX) dividend payment is scheduled for June 30, 2025.
What is the beta indicator for Becton Dickinson?
Becton Dickinson (BDX) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.